| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,670,000 |
| Market
Cap: |
90.88(M) |
| Last
Volume: |
940,193 |
Avg
Vol: |
714,677 |
| 52
Week Range: |
$0.754 - $7.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Assertio Therapeutics is a pharmaceutical company. Co.'s primary marketed products include: INDOCIN® (indomethacin) Suppositories and INDOCIN® (indomethacin) Oral Suspension, which is a suppository form and oral solution of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis and osteoarthritis; CAMBIA® (diclofenac potassium for oral solution), which is a prescription NSAID indicated for the acute treatment of migraine attacks in adults; and Otrexup® (methotrexate) injection, used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Saks Samuel R |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$18,354 |
D/D |
(966) |
2,897 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$22,762 |
D/D |
(1,198) |
10,665 |
|
- |
|
| Zenoff David B |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$25,859 |
D/D |
(1,361) |
22,098 |
|
- |
|
| Shively Richard Scott |
SVP & Chief Commercial Officer |
• – – |
2015-12-01 |
4 |
D |
$19.00 |
$31,255 |
D/D |
(1,645) |
2,730 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$25,859 |
D/D |
(1,361) |
82,502 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2015-12-01 |
4 |
D |
$19.00 |
$227,639 |
D/D |
(11,981) |
53,676 |
|
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2015-12-01 |
4 |
D |
$19.00 |
$265,240 |
D/D |
(13,960) |
152,557 |
|
- |
|
| Anido Vicente Jr |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$25,859 |
D/D |
(1,361) |
2,502 |
|
- |
|
| Srinivas Rao |
SVP and Chief Medical Officer |
• – – |
2015-12-01 |
4 |
D |
$19.00 |
$31,255 |
D/D |
(1,645) |
4,374 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-12-01 |
4 |
D |
$19.00 |
$1,074,982 |
D/D |
(56,578) |
51,847 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-10-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
63,561 |
346,888 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-10-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
63,561 |
0 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2015-09-30 |
4 |
OE |
$3.28 |
$80,200 |
D/D |
20,000 |
80,000 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-09-29 |
4 |
OE |
$6.11 |
$408,158 |
D/D |
63,561 |
63,561 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-06-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
63,021 |
283,327 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-06-23 |
4 |
GA |
$0.00 |
$0 |
D/D |
63,021 |
0 |
|
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2015-06-12 |
4 |
S |
$20.70 |
$103,500 |
D/D |
(5,000) |
138,153 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-06-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
220,306 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2015-05-12 |
4 |
OE |
$6.11 |
$304,134 |
D/D |
45,679 |
61,411 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2015-05-12 |
4 |
OE |
$6.18 |
$61,800 |
D/D |
10,000 |
60,000 |
|
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2015-04-08 |
4 |
OE |
$3.09 |
$338,010 |
D/D |
54,710 |
143,153 |
|
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2015-01-20 |
4 |
OE |
$5.03 |
$95,570 |
D/D |
19,000 |
88,443 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2014-12-19 |
4 |
OE |
$8.36 |
$340,252 |
D/D |
40,700 |
56,432 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2014-12-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
37,198 |
180,606 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2014-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
37,198 |
15,732 |
|
- |
|
165 Records found
|
|
Page 6 of 7 |
|
|
0.09 (8.57%) 
